Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

<p>Abstract</p> <p>We describe a novel strategy in which two inhibitors of HIV viral entry were incorporated into a single molecule. This bifunctional fusion inhibitor consists of an antibody blocking the binding of HIV to its co-receptor CCR5, and a covalently linked peptide which...

Full description

Bibliographic Details
Main Authors: Cammack Nick, Fischer Stephan, Zhang Jun, Rao Eileen, Ji Changhua, Jekle Andreas, Kopetzki Erhard, Sankuratri Surya, Heilek Gabrielle
Format: Article
Language:English
Published: BMC 2008-05-01
Series:Virology Journal
Online Access:http://www.virologyj.com/content/5/1/56
id doaj-2f40e1c837204ad49811da95d8786d5a
record_format Article
spelling doaj-2f40e1c837204ad49811da95d8786d5a2020-11-25T01:10:53ZengBMCVirology Journal1743-422X2008-05-01515610.1186/1743-422X-5-56Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1Cammack NickFischer StephanZhang JunRao EileenJi ChanghuaJekle AndreasKopetzki ErhardSankuratri SuryaHeilek Gabrielle<p>Abstract</p> <p>We describe a novel strategy in which two inhibitors of HIV viral entry were incorporated into a single molecule. This bifunctional fusion inhibitor consists of an antibody blocking the binding of HIV to its co-receptor CCR5, and a covalently linked peptide which blocks envelope mediated virus-cell fusion. This novel bifunctional molecule is highly active on CCR5- and X4-tropic viruses in a single cycle assay and a reporter cell line with IC<sub>50 </sub>values of 0.03–0.05 nM. We demonstrated that both inhibitors contribute to the antiviral activity. In the natural host peripheral blood mononuclear cells (PBMC) the inhibition of CXCR4-tropic viruses is dependant on the co-expression of CCR5 and CXCR4 receptors. This bifunctional inhibitor may offer potential for improved pharmacokinetic parameters for a fusion inhibitor in humans and the combination of two active antiviral agents in one molecule may provide better durability in controlling the emergence of resistant viruses.</p> http://www.virologyj.com/content/5/1/56
collection DOAJ
language English
format Article
sources DOAJ
author Cammack Nick
Fischer Stephan
Zhang Jun
Rao Eileen
Ji Changhua
Jekle Andreas
Kopetzki Erhard
Sankuratri Surya
Heilek Gabrielle
spellingShingle Cammack Nick
Fischer Stephan
Zhang Jun
Rao Eileen
Ji Changhua
Jekle Andreas
Kopetzki Erhard
Sankuratri Surya
Heilek Gabrielle
Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1
Virology Journal
author_facet Cammack Nick
Fischer Stephan
Zhang Jun
Rao Eileen
Ji Changhua
Jekle Andreas
Kopetzki Erhard
Sankuratri Surya
Heilek Gabrielle
author_sort Cammack Nick
title Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1
title_short Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1
title_full Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1
title_fullStr Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1
title_full_unstemmed Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1
title_sort closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of hiv-1
publisher BMC
series Virology Journal
issn 1743-422X
publishDate 2008-05-01
description <p>Abstract</p> <p>We describe a novel strategy in which two inhibitors of HIV viral entry were incorporated into a single molecule. This bifunctional fusion inhibitor consists of an antibody blocking the binding of HIV to its co-receptor CCR5, and a covalently linked peptide which blocks envelope mediated virus-cell fusion. This novel bifunctional molecule is highly active on CCR5- and X4-tropic viruses in a single cycle assay and a reporter cell line with IC<sub>50 </sub>values of 0.03–0.05 nM. We demonstrated that both inhibitors contribute to the antiviral activity. In the natural host peripheral blood mononuclear cells (PBMC) the inhibition of CXCR4-tropic viruses is dependant on the co-expression of CCR5 and CXCR4 receptors. This bifunctional inhibitor may offer potential for improved pharmacokinetic parameters for a fusion inhibitor in humans and the combination of two active antiviral agents in one molecule may provide better durability in controlling the emergence of resistant viruses.</p>
url http://www.virologyj.com/content/5/1/56
work_keys_str_mv AT cammacknick closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT fischerstephan closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT zhangjun closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT raoeileen closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT jichanghua closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT jekleandreas closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT kopetzkierhard closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT sankuratrisurya closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
AT heilekgabrielle closingtwodoorsofviralentryintramolecularcombinationofacoreceptorandfusioninhibitorofhiv1
_version_ 1725173639604600832